SCHEMBL7659965

SCHEMBL7659965

CC(=O)NCCc1nc2ccc(C#N)cc2[nH]1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.63
PIN1 Q13526 1/20 0.52
SLC40A1 Q9NP59 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
GSK3B P49841 3/20 0.47
F9 P00740 1/20 0.47
CSNK1A1 P48729 2/20 0.46
CSNK1D P48730 2/20 0.46
CSNK1G2 P78368 2/20 0.46
THRB P10828 2/20 0.46
CTSS P25774 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2B Q13224 1/20 0.46
LMNA P02545 1/20 0.46
KMT2A Q03164 2/20 0.45
POLB P06746 1/20 0.45
ABL1 P00519 1/20 0.44
ALDH1A1 P00352 1/20 0.43
MLLT1 Q03111 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7659959 0.90 HTT (0.63) HTTSMN1; SMN2F9THRBCTSS
SCHEMBL7654762 0.79 HTT (0.64) HTTSMN1; SMN2F9THRBLMNA
SCHEMBL13406119 0.79 THRB (0.59) SMN1; SMN2THRBCTSSLMNAKMT2A
SCHEMBL16136353 0.78 HTT (1.00) HTTSMN1; SMN2THRBLMNAALDH1A1
SCHEMBL4069591 0.77 PIN1 (0.63) PIN1GSK3BCSNK1A1CSNK1DCSNK1G2
SCHEMBL13406122 0.77 CTSS (0.65) SMN1; SMN2THRBCTSSLMNA
SCHEMBL7655135 0.76 RAD52 (0.61) PIN1SMN1; SMN2GSK3BCSNK1A1CSNK1D
SCHEMBL22553665 0.76 GRIN1 (0.53) PIN1GSK3BCSNK1A1CSNK1DCSNK1G2
SCHEMBL7653726 0.76 TDP1 (0.59) PIN1SMN1; SMN2GSK3BCSNK1A1CSNK1D
SCHEMBL7653331 0.76 GRIN1 (0.53) HTTPIN1SMN1; SMN2GSK3BCSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6399642-B2 TRIS BENZIMIDAZOLES; FUNGICIDES, ANTICARCINOGENIC AGENTS, ENZYME INHIBITOR RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2002-06-04 US disclosed
US-20010009919-A1 Heterocyclic topoisomerase poisons RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2001-07-26 US disclosed
US-6221892-B1 Heterocyclic topoisomerase poisons THE STATE OF UNIVERSITY OF NEW JERSEY, RUTGERS 2001-04-24 US disclosed
EP-1054870-A1 HETEROCYCLIC TOPOISOMERASE POISONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2000-11-29 EP disclosed
US-6063801-A Heterocyclic topoisomerase poisons RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2000-05-16 US disclosed
WO-1999041241-A1 HETEROCYCLIC TOPOISOMERASE POISONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 1999-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010009919-A1 Heterocyclic topoisomerase poisons TOP1, TOP2A, TOP2B HTT 1871/4885PIN1 1184/4885SLC40A1 3287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.